Dr. Ajit Kumar Bisen, MD

Dr. Bisen practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Bisen's NPI, 1891924544, was assigned on July 2, 2009. Dr. Bisen graduated from St. George's University School of Medicine in 2009. Dr. Bisen holds Texas license P5260.

Dr. Bisen's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Bisen's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bisen practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bisen's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bisen is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Bisen's licenses on file in 11 states: Texas, Arizona, Georgia, Tennessee, Washington, Alabama, Louisiana, Mississippi, Pennsylvania, Ohio and North Carolina.

Dmand AI lists deep vein thrombosis (DVT), immune deficiency disease and insomnia among the conditions Dr. Bisen treats.

CMS data shows 227 Medicare services from Dr. Bisen across 3 procedure codes in 2024, for 85 Medicare patients. Medicare paid $24,931 for them. Every service was in an office.

CMS counts 85 Medicare patients who saw Dr. Bisen in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have cancer, and 73% have high cholesterol. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bisen's median patient age at 65, with 97% women.

In 2024, Dr. Bisen wrote 217 Medicare Part D claims for 63 patients. 65% of them were for generic drugs. CMS names the drug for 129 of them, across 5 drugs with 11 or more claims each, at $963,251 in total drug cost. In 2023, CMS named 155 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Bisen for performance year 2024, reported as part of a group. Dr. Bisen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bisen as offering telehealth.

Dmand AI links 5 papers to Dr. Bisen, published from 2013 to 2023. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide and Doxorubicin. Dr. Bisen's most frequent co-authors are Sausan Z. Abouharb, MD, Beatriz Elena Adrada, MD and Banu K. Arun, MD.

Dmand AI links Dr. Bisen to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Triple Negative Breast Neoplasms and Breast Neoplasms.

CMS Open Payments shows 55 general payments to Dr. Bisen from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Gilead Sciences, Inc. paid the most, $9,678.

Dr. Bisen graduated from St. George's University School of Medicine in 2009. Dr. Bisen is a member of ASCO.

Dr. Bisen is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.